BrainswayBWAY
About: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Employees: 120
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,192% more call options, than puts
Call options by funds: $853K | Put options by funds: $66K
34% more capital invested
Capital invested by funds: $56.7M [Q1] → $75.7M (+$19M) [Q2]
14.62% more ownership
Funds ownership: 15.86% [Q1] → 30.48% (+14.62%) [Q2]
0% more funds holding
Funds holding: 42 [Q1] → 42 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju | 8%upside $17 | Buy Reiterated | 25 Aug 2025 |
Northland Capital Markets Carl Byrnes | 21%upside $19 | Outperform Maintained | 14 Aug 2025 |
Financial journalist opinion
Based on 8 articles about BWAY published over the past 30 days
